Scott provides updates on efforts to get FDA approval for fluvoxamine as a COVID-19 treatment and reports on the early approval of Paxlovid.
Longer summary
This post is an addendum to a previous article about Luvox and COVID-19 treatment. It updates readers on recent developments in the effort to get FDA approval for fluvoxamine (Luvox) as a COVID-19 treatment. Scott reports that Dr. Ed Mills and colleagues have found a way to submit an Emergency Use Authorization (EUA) application to the FDA for fluvoxamine, despite the initial hurdle of not having a sponsoring drug company. The post also mentions the FDA's approval of Paxlovid, another COVID-19 drug, which happened earlier than expected according to prediction markets.
Shorter summary